Monoclonal antibodies (mAb) are central to the treatment of several types of malignancy. However, these reagents are subject to particular types of resistance. Several resistance mechanisms are regulated by the inhibitory FcγRIIB. We recently developed mAbs to block FcγRIIB and provided proof-of-concept for their ability to overcome FcγRIIB-mediated resistance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801439 | PMC |
| http://dx.doi.org/10.1080/2162402X.2015.1069939 | DOI Listing |
Publication Analysis
Top Keywords
inhibitory fcγriib
8
resistance
4
resistance futile
4
futile targeting
4
targeting inhibitory
4
fcγriib cd32b
4
cd32b maximize
4
maximize immunotherapy
4
immunotherapy monoclonal
4
monoclonal antibodies
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!